3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.

Adjuvants, Immunologic Animals Female Heterocyclic Compounds, 3-Ring / pharmacology Immunity, Humoral / immunology Macaca mulatta / immunology Male Membrane Glycoproteins / agonists Plasma Cells / drug effects Stearic Acids / pharmacology Toll-Like Receptor 7 / agonists Toll-Like Receptor 8 / agonists env Gene Products, Human Immunodeficiency Virus / immunology

Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
19 06 2020
Historique:
received: 30 01 2020
accepted: 22 05 2020
entrez: 21 6 2020
pubmed: 21 6 2020
medline: 9 2 2021
Statut: ppublish

Résumé

A fundamental challenge in vaccinology is learning how to induce durable antibody responses. Live viral vaccines induce antibody responses that last a lifetime, but those induced with subunit vaccines wane rapidly. Studies in mice and humans have established that long-lived plasma cells (LLPCs) in the bone marrow (BM) are critical mediators of durable antibody responses. Here, we present data that adjuvanting an HIV-1 clade C 1086.C-derived gp140 immunogen (Env) with a novel synthetic Toll-like receptor (TLR)-7/8 agonist named 3M-052 formulated in poly(lactic-

Identifiants

DOI: 10.1126/sciimmunol.abb1025 PMID: 32561559 PMC: PMC8109745
pubmed: 32561559
pii: 5/48/eabb1025
doi: 10.1126/sciimmunol.abb1025
pmc: PMC8109745
mid: NIHMS1610047
pii:
doi:

Substances chimiques

Adjuvants, Immunologic 0
Heterocyclic Compounds, 3-Ring 0
Membrane Glycoproteins 0
Stearic Acids 0
TLR8 protein, mouse 0
Tlr7 protein, mouse 0
Toll-Like Receptor 7 0
Toll-Like Receptor 8 0
env Gene Products, Human Immunodeficiency Virus 0
gp140 envelope protein, Human immunodeficiency virus 1 0
MEDI9197 16598XQ2BT

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : K01 OD023039
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI131251
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI125068
Pays : United States
Organisme : NCRR NIH HHS
ID : P51 RR000165
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI088575
Pays : United States

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Biologics. 2008 Mar;2(1):97-105
pubmed: 19707432
Gynecol Oncol. 2017 Jul;146(1):196-204
pubmed: 28442134
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
J Immunol. 2018 Jul 1;201(1):98-112
pubmed: 29769270
Nat Immunol. 2011 Jun;12(6):509-17
pubmed: 21739679
J Pharm Sci. 2012 Jan;101(1):17-20
pubmed: 21918987
JCI Insight. 2017 Mar 23;2(6):e91020
pubmed: 28352660
Curr Opin Immunol. 2019 Aug;59:31-41
pubmed: 30978666
J Virol. 2018 Mar 28;92(8):
pubmed: 29386288
Stat Biopharm Res. 2009 Feb 1;1(1):81-91
pubmed: 20072667
J Infect Dis. 2017 Apr 15;215(8):1255-1263
pubmed: 28329190
PLoS One. 2018 Apr 26;13(4):e0194266
pubmed: 29698406
J Immunol Methods. 2014 Feb;404:1-12
pubmed: 24316020
Annu Rev Med. 2015;66:423-37
pubmed: 25341006
Cell Rep. 2020 Mar 24;30(12):3964-3971.e7
pubmed: 32209459
Nature. 2008 May 29;453(7195):667-71
pubmed: 18449194
NPJ Vaccines. 2017 Sep 8;2:25
pubmed: 29263880
J Exp Med. 2007 Oct 29;204(11):2733-46
pubmed: 17954572
Expert Rev Vaccines. 2012 Jun;11(6):645-57
pubmed: 22873123
Nat Commun. 2019 Feb 18;10(1):798
pubmed: 30778066
J Immunol. 2014 Nov 1;193(9):4527-36
pubmed: 25246494
Immunol Rev. 2013 Sep;255(1):243-55
pubmed: 23947360
PLoS One. 2016 Feb 10;11(2):e0148984
pubmed: 26862758
J Immunol Methods. 2014 Jul;409:107-16
pubmed: 24787274
Annu Rev Immunol. 2017 Apr 26;35:255-284
pubmed: 28142324
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Viral Immunol. 2018 Mar;31(2):114-116
pubmed: 29131713
PLoS Pathog. 2007 Nov;3(11):e169
pubmed: 17983270
J Exp Med. 2006 Feb 20;203(2):413-24
pubmed: 16461338
Methods Mol Biol. 2009;485:395-405
pubmed: 19020839
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15190-4
pubmed: 16219698
Blood Adv. 2017 Nov 17;1(25):2329-2342
pubmed: 29296883
Expert Opin Biol Ther. 2013 Feb;13(2):197-207
pubmed: 23130709
Cell Host Microbe. 2014 Jul 9;16(1):115-27
pubmed: 24981333
J Control Release. 2016 Dec 28;244(Pt A):98-107
pubmed: 27847326
Expert Rev Vaccines. 2007 Aug;6(4):471-4
pubmed: 17668999
Immunity. 2015 Jul 21;43(1):132-45
pubmed: 26187412
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830870
Clin Vaccine Immunol. 2017 Jul 5;24(7):
pubmed: 28490424
Cytometry A. 2011 Aug;79(8):603-12
pubmed: 21735545
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Immunity. 1998 Mar;8(3):363-72
pubmed: 9529153
Nature. 2011 Feb 24;470(7335):543-7
pubmed: 21350488
Immunity. 2019 May 21;50(5):1172-1187.e7
pubmed: 31076359
Expert Rev Vaccines. 2011 Dec;10(12):1731-42
pubmed: 22085176
Nat Immunol. 2013 Dec;14(12):1256-65
pubmed: 24162774
Nat Protoc. 2009;4(3):372-84
pubmed: 19247287
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):518-23
pubmed: 25550504
J Allergy Clin Immunol. 2014 Jul;134(1):3-10; quiz 11
pubmed: 25117798
Elife. 2019 May 15;8:
pubmed: 31090539
Hum Vaccin Immunother. 2017 Aug 3;13(8):1789-1797
pubmed: 28426274
J Virol. 2013 Apr;87(8):4185-201
pubmed: 23365441
Curr Opin Immunol. 1998 Jun;10(3):252-8
pubmed: 9638360
Virology. 2007 Dec 5;369(1):153-67
pubmed: 17698160
Immunity. 2010 Oct 29;33(4):492-503
pubmed: 21029960
Nat Med. 2013 Dec;19(12):1597-608
pubmed: 24309663
Cell Rep. 2016 Nov 22;17(9):2195-2209
pubmed: 27880897
Blood. 2012 Mar 1;119(9):2044-55
pubmed: 22246032
Nature. 2005 Nov 17;438(7066):364-8
pubmed: 16292312
J Immunol. 1972 Dec;109(6):1386-94
pubmed: 4673617
Immunol Rev. 2010 Jul;236:125-38
pubmed: 20636813
J Control Release. 2006 Feb 21;110(3):566-73
pubmed: 16360956
J Infect Dis. 2011 Jul 1;204(1):164-73
pubmed: 21628671
J Virol. 2014 Jul;88(14):7715-26
pubmed: 24807721
JCI Insight. 2018 May 17;3(10):
pubmed: 29769448
Cell. 2013 Oct 24;155(3):531-9
pubmed: 24243013
Science. 2006 Dec 22;314(5807):1936-8
pubmed: 17185603
J Nanobiotechnology. 2014 Apr 26;12:17
pubmed: 24766820
J Virol. 2017 Jan 31;91(4):
pubmed: 27928002
Vaccine. 2011 Jul 26;29(33):5434-42
pubmed: 21641953
Front Immunol. 2018 Nov 16;9:2673
pubmed: 30505309

Auteurs

Sudhir Pai Kasturi (SP)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
ORCID: 0000-0002-6421-2040

Mohammed Ata Ur Rasheed (MAU)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
Division of Microbiology and Immunology and Rollins Research Center, Emory University, 1510 Clifton Road, Atlanta, GA, USA.
ORCID: 0000-0002-8819-3112

Colin Havenar-Daughton (C)

Division of Vaccine Discovery, La Jolla Institute of Immunology, La Jolla, CA, USA.
ORCID: 0000-0002-2880-3927

Mathew Pham (M)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
ORCID: 0000-0002-4788-9658

Traci Legere (T)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
ORCID: 0000-0001-6393-719X

Zarpheen Jinnah Sher (ZJ)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.

Yevgeny Kovalenkov (Y)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
ORCID: 0000-0003-2396-7962

Sanjeev Gumber (S)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
ORCID: 0000-0001-9048-2717

Jessica Y Huang (JY)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
ORCID: 0000-0001-8674-5924

Raphael Gottardo (R)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
ORCID: 0000-0002-3867-0232

William Fulp (W)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Alicia Sato (A)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
ORCID: 0000-0001-8371-8007

Sheetal Sawant (S)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
Department of Molecular Genetics and Microbiology and Department of Immunology, Duke University, NC, USA.
ORCID: 0000-0002-1109-7907

Sherry Stanfield-Oakley (S)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
ORCID: 0000-0002-6347-1956

Nicole Yates (N)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
Department of Molecular Genetics and Microbiology and Department of Immunology, Duke University, NC, USA.
ORCID: 0000-0003-2678-1311

Celia LaBranche (C)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
ORCID: 0000-0002-6653-6655

S Munir Alam (SM)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
ORCID: 0000-0003-0941-0703

Georgia Tomaras (G)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
Department of Molecular Genetics and Microbiology and Department of Immunology, Duke University, NC, USA.

Guido Ferrari (G)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
Department of Molecular Genetics and Microbiology and Department of Immunology, Duke University, NC, USA.

David Montefiori (D)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
ORCID: 0000-0003-0856-6319

Jens Wrammert (J)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
ORCID: 0000-0002-1733-4424

Francois Villinger (F)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
New Iberia Research Center, University of Louisiana Lafayette, New Iberia, LA, USA.
ORCID: 0000-0002-7790-2008

Mark Tomai (M)

3M Drug Delivery Systems, St. Paul, MN, USA.
ORCID: 0000-0002-6362-9151

John Vasilakos (J)

3M Drug Delivery Systems, St. Paul, MN, USA.

Christopher B Fox (CB)

Infectious Disease Research Institute, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.
ORCID: 0000-0002-4644-2619

Steven G Reed (SG)

Infectious Disease Research Institute, Seattle, WA, USA.
HDT Bio, Seattle, WA, USA.

Barton F Haynes (BF)

Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.

Shane Crotty (S)

Division of Vaccine Discovery, La Jolla Institute of Immunology, La Jolla, CA, USA.
Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego (UCSD), La Jolla, CA, USA.
ORCID: 0000-0002-6484-6262

Rafi Ahmed (R)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA. bpulend@stanford.edu rahmed@emory.edu.
Division of Microbiology and Immunology and Rollins Research Center, Emory University, 1510 Clifton Road, Atlanta, GA, USA.
ORCID: 0000-0002-9591-2621

Bali Pulendran (B)

Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA. bpulend@stanford.edu rahmed@emory.edu.
Departments of Pathology and Microbiology & Immunology, Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.
ORCID: 0000-0001-6517-4333

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Adjuvants immunologiques › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Eucaryotes › Animaux › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques 3 noyaux › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité humorale › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Plasmocytes › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Lipides › Acides gras › Acides stéariques › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs de reconnaissance de motifs moléculaires › Récepteurs de type Toll › Récepteur de type Toll-7 › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs de reconnaissance de motifs moléculaires › Récepteurs de type Toll › Récepteur de type Toll-8 › 3M-052, a synthetic TLR-7/8 agonist, induces...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Produits du gène env › Produits du gène env du virus de l'immunodéficience humaine › 3M-052, a synthetic TLR-7/8 agonist, induces...